Table 1.
UCK2 in tumor development and chemotherapy.
| Features | Subjects | Ref. |
|---|---|---|
| UCK2 upregulation in | Lung cancer | (19, 20) |
| Breast cancer | (21, 22) | |
| Ovarian carcinoma | (23) | |
| Colorectal cancer | (24) | |
| Neuroblastoma | (6, 8) | |
| Pancreatic tumor | (25) | |
| Hepatocellular carcinoma | (26–29) | |
| Burkitt lymphomas | (30) | |
| Acute lymphoblastic leukemia | (30) | |
| UCK2 as a prognostic marker in | Hepatocellular carcinoma | (27–29, 31–33) |
| Pancreatic cancer | (34) | |
| Lung cancer | (20) | |
| Testicular germ cell tumors | (35) | |
| Endometrial cancer | (36, 37) | |
| Regulation of UCK2 expression by | Genomic amplification | (27) |
| Infection of Epstein–Barr virus | (38) | |
| m6A modification | (39) | |
| Hypoxia | (40) | |
| Cytotoxic ribonucleoside analogs of UCK2 | TAS-106 | (25, 41, 42) |
| EUrd | (42) | |
| 5-FU | (43) | |
| RX-3117 | (44, 45) |